Document Detail


Effects of Citrate Acid Concentrate (Citrasate®) on Heparin N Requirements and Hemodialysis Adequacy: A Multicenter, Prospective Noninferiority Trial.
MedLine Citation:
PMID:  22269855     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background: Citrasate®, citric acid dialysate (CD), contains 2.4 mEq of citric acid (citrate), instead of acetic acid (acetate) as in standard bicarbonate dialysate. Previous studies suggest CD may improve dialysis adequacy and decrease heparin requirements, presumably due to nonsystemic anticoagulant effects in the dialyzer. Methods: We prospectively evaluated 277 hemodialysis patients in eight outpatient facilities to determine if CD with reduced heparin N (HN) would maintain dialyzer clearance. Subjects progressed through four study periods [baseline (B): bicarbonate dialysate + 100% HN; period 1 (P1): CD + 100% HN; period 2 (P2): CD + 80% HN; period 3 (P3): CD + 66.7% HN]. The predefined primary endpoint was noninferiority (margin -8%) of the percent change in mean dialyzer conductivity clearance between baseline and P2. Results: Subjects were 57.4% male, 41.7% white, 54.3% black, and 44.4% diabetic; mean age was 59 ± 14.4 years; mean time on dialysis was 1,498 ± 1,165 days; 65.7% had arteriovenous fistula, 19.9% arteriovenous graft, 14.4% catheters, and 27.8% used antiplatelet agents. Mean dialyzer clearance increased 0.9% (P1), 1.0% (P2), and 0.9% (P3) with CD despite heparin reduction. SpKt/V remained stable (B: 1.54 ± 0.29; P1: 1.54 ± 0.28; P2: 1.55 ± 0.27; P3: 1.54 ± 0.26). There was no significant difference in dialyzer/dialysis line thrombosis, post-HD time to hemostasis, percent of subjects with adverse events (AEs), or study-related AEs. Conclusions: CD was safe, effective, and met all study endpoints. Dialyzer clearance increased approximately 1% with CD despite 20-33% heparin reduction. Over 92% of P3 subjects demonstrated noninferiority of dialyzer clearance with CD and 33% HN reduction. There was no significant difference in dialyzer clotting, bleeding, or adverse events.
Authors:
Jeffrey J Sands; Peter Kotanko; Jonathan H Segal; Chiang-Hong Ho; Len Usvat; Amy Young; Mary Carter; Olga Sergeyeva; Lisa Korth; Eileen Maunsell; Yueping Zhu; Mahesh Krishnan; Jose A Diaz-Buxo
Related Documents :
10681345 - Enzymes catalyzing the early steps of clavulanic acid biosynthesis are encoded by two s...
22530595 - Hemicelluloses prior to aspen chemi-thermomechanical pulping: pre-extraction, separatio...
2630475 - Efficacy of nalidixic acid in the treatment of acute bloody diarrhea.
10567375 - Regulation of the biosynthesis of n-acetylglucosaminylpyrophosphoryldolichol, feedback ...
22063415 - Injection of conjugated linoleic acid into beef strip loins.
10939285 - Characterisation of kynurenine pathway metabolism in human astrocytes and implications ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-20
Journal Detail:
Title:  Blood purification     Volume:  33     ISSN:  1421-9735     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8402040     Medline TA:  Blood Purif     Country:  -    
Other Details:
Languages:  ENG     Pagination:  199-204     Citation Subset:  -    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Fresenius Medical Care North America, Celebration, Fla., USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ghrelin Protects H9c2 Cardiomyocytes from Angiotensin II-induced Apoptosis Through the Endoplasmic R...
Next Document:  Prevalence of Antibiotic Resistance in Fecal Flora of Patients Undergoing Transrectal Ultrasound-Gui...